Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu Estalis®:Novartis Pharma Schweiz AG
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
G03FA01 - Norethisterone and EstrogenATC-DDD Version 2016. Source: WHO
G - Genito Urinary System and Sex Hormones
G03 - Sex Hormones and Modulators Of The Genital System

Other hormones, see H - Systemic hormonal preparations, excl. sex hormones and insulins.
Sex hormones used only in the treatment of cancer (often selected strengths) are classified in L - Antineoplastic and immunomodulating agents.

The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability. The DDDs of depot preparations are calculated as the dose divided by the dosing interval.

G03F - Progestogens and Estrogens in Combination

This group comprises combined preparations used in the treatment of menopausal symptoms, menstrual irregularities etc.
Hormonal contraceptives, see G03A.

The DDDs for combined preparations of estrogens and progestogens are based on use in postmenopausal substitution therapy in cycles of 28 days. Thus, the DDD is 0.75 and 1 UD for 21 and 28 tablets cycle packages, respectively.

G03FA - Progestogens and Estrogens, Fixed Combinations

This group comprises preparations, which contain combinations of progestogens and estrogens. Sequential preparations are classified in G03FB. Combination packages with separate tablets containing progestogens and estrogens intended to be taken together are also classified in this group. The preparations are classified at 5th levels according to the progestogen. At each 5th level various estrogens may occur.
Combinations of progestogens and estrogens used as contraceptives are classified in G03A.

G03FA01 - Norethisterone and Estrogen
2020 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home